MINERVA NEUROSCIENCES INC (NERV)
Health Care · Clinical-stage CNS biopharmaceutical · NASDAQ
Clinical-stage biotech developing roluperidone, a novel treatment for schizophrenia and other CNS disorders.
What MINERVA NEUROSCIENCES INC does
Minerva Neurosciences is a clinical-stage biopharmaceutical company focused on developing treatment candidates for serious psychiatric and neurological disorders. The company's lead candidate is roluperidone, which is being evaluated in clinical trials for schizophrenia and other central nervous system indications. Minerva is advancing its pipeline through clinical development with a focus on CNS disorders where there is significant unmet medical need.
Themes: ["CNS / neuropsychiatric disorders"]
Fundamentals
- Price$4.72 as of 2026-07-09 close
- Market cap$215M as of 2026-07-10
- 1-year return+175.7% as of 2026-07-09 close
- P/E149.47 as of 2026-07-10
- Net margin+4.7% as of 2026-07-10
- ROE-169.6% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Beta-0.05 as of 2026-07-10
Key risks (from latest filing)
["Lead candidate roluperidone is in clinical development with no guarantee of regulatory approval or commercialization success, which could materially harm the business if development is delayed or fails."]
Competitors & peers
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.